ArticleMovement disorders clinical practice2020
The Montreal Cognitive Assessment: Is It Suitable for Identifying Mild Cognitive Impairment in Parkinson's Disease?
Article in Movement disorders clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Dual-Task Effects During a Motor-Cognitive Task in Parkinson's Disease: Patterns of Prioritization and the Influence of Cognitive Status.Neurorehabilitation and neural repair · 2021Trial
- A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson's disease.Scientific reports · 2026Article
- Data-driven clinical decision support tool for diagnosing mild cognitive impairment in Parkinson's disease.NPJ Parkinson's disease · 2026Article
- A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson's Disease.Research square · 2025Article
- Multi-cohort machine learning identifies predictors of cognitive impairment in Parkinson's disease.NPJ digital medicine · 2025Article
- Functional cognitive performance augments cognitive screening data in older adults.Frontiers in aging neuroscience · 2025Article
- Screening for Cognitive Impairment in Movement Disorders: Comparison of the Montreal Cognitive Assessment and Quick Mild Cognitive Impairment Screen in Parkinson's Disease and Lewy Body Dementia.Journal of Alzheimer's disease reports · 2024Article
- Early identification of subjective cognitive functional decline among patients with Parkinson's disease: a longitudinal pilot study.Scientific reports · 2022Article
- Regression-Based Normative Data for the Montreal Cognitive Assessment (MoCA) and Its Memory Index Score (MoCA-MIS) for Individuals Aged 18-91.Journal of clinical medicine · 2022Article
- Capturing Subjective Mild Cognitive Decline in Parkinson's Disease.Brain sciences · 2022Article
- Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test.NPJ Parkinson's disease · 2022Article
- Patients' Self-Report and Handwriting Performance Features as Indicators for Suspected Mild Cognitive Impairment in Parkinson's Disease.Sensors (Basel, Switzerland) · 2022Article
- Internetwork Connectivity Predicts Cognitive Decline in Parkinson's and Is Altered by Genetic Variants.Frontiers in aging neuroscience · 2022Article
- Gender Differences in State Anxiety Related to Daily Function Among Older Adults During the COVID-19 Pandemic: Questionnaire Study.JMIR aging · 2021Article
- DailyCog: A Real-World Functional Cognitive Mobile Application for Evaluating Mild Cognitive Impairment (MCI) in Parkinson's Disease.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdministering an abbreviated global cognitive test, such as the Montreal Cognitive Assessment (MoCA), is necessary for the recommended first-level diagnostic criteria for mild cognitive impairment (MCI) in Parkinson's disease (PD). Level II requires administering cognitive functioning neuropsychological tests. The MoCA's suitability for identifying PD-MCI is questionable and, despite the importance of cognitive deficits reflected through daily functioning in identifying PD-MCI, knowledge about it is scarce.
objectivesTo explore neuropsychological test scores of patients with PD who were categorized based on their MoCA scores and to analyze correlations between this categorization and patients' self-reports about daily functional-related cognitive abilities.
methodsA total of 78 patients aged 42 to 78 years participated: 46 with low MoCA scores (22-25) and 32 with high MoCA scores (26-30). Medical assessments and level II neuropsychological assessment tools were administered along with standardized self-report questionnaires about daily functioning that reflects patients' cognitive abilities.
resultsA high percentage of the low MoCA group obtained neuropsychological test scores within the normal range; a notable number in the high MoCA group were identified with MCI-level scores on various neuropsychological tests. Suspected PD-MCI according to the level I criteria did not correspond well with the level II criteria. Positive correlations were found among the 3 self-report questionnaires.
conclusionsThese results support the ongoing discussion of the complexity of capturing PD-MCI. Considering the neuropsychological tests results, assessments that reflect cognitive encounters in real life daily confrontations are warranted among people diagnosed with PD who are at risk for cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.